The Mission Report

MissionIR Market Pulse Clients

CytRx Corporation (CYTR)

CytRx Corp., a biopharmaceutical research and development company, specializes in the enhanced delivery of proven oncology therapies to treat cancer. The company’s novel linker platform technology can be utilized with multiple chemotherapeutic agents and could allow for greater concentration of drug at tumor sites while minimizing side effects.

View Profile

FluoroPharma Medical (FPMI)

FluoroPharma Medical, Inc. is a biopharmaceutical company focused on discovering and developing patented Positron Emission Tomography (PET) imaging products to improve patient management by evaluating cardiac disease at the cellular and molecular levels. The company is currently advancing four different imaging agents to fulfill multiple critical unmet medical needs.

View Profile

Galena Biopharma, Inc. (GALE)

Galena Biopharma, Inc. is focused on developing and commercializing peptide vaccine immunotherapies that harness the patient’s own immune system to identify and destroy cancer cells. Utilizing peptide immunogens has many clinical advantages, including an excellent safety profile and long-lasting protection through immune system activation and convenient delivery.

View Profile

 

Aegis Healthcare Conference

The Wynn, Las Vegas

September 25th - 28th, 2013

 

Aegis Capital Corp. is a full service retail and institutional broker-dealer located in New York City. Aegis Capital's management is committed
to providing the highest level of service to its clients. The firm realizes this goal by running an independent, conflict-free platform that is
focused on enhancing the goals of clients by bringing unencumbered advice, which enables them to freely create a plan centered on each client.
Aegis Capital continues to meet the challenging and changing markets by investing in world-class services such as access to independent
research for its financial advisors and their clients from JP Morgan, Bloomberg, Moody's, Lipper, Best Independent Research LLC,
and Argus Research.

Aastrom Biosciences, Inc. (ASTM)

Aastrom Biosciences, Inc. (NASDAQ: ASTM) develops patient-specific cell products for treating severe, chronic ischemic cardiovascular diseases. The company is developing ixmyelocel-T, a multicellular therapy expanded from a patient's own bone marrow and delivered directly to damaged tissues. Ixmyelocel-T is in late-stage clinical development, including a Phase III clinical program to study patients with critical limb ischemia and a Phase IIb clinical trial in patients with ischemic dilated cardiomyopathy. For more information, visit the company’s website at www.aastrom.com.

Acorda Therapeutics, Inc. (ACOR)

Acorda Therapeutics, Inc. (NASDAQ: ACOR) is a commercial-stage biopharmaceutical company that engages in identifying, developing and bringing to market therapies for multiple sclerosis (MS), spinal cord injury and other central nervous system disorders. Acorda’s products include: Ampyra (dalfampridine), a potassium channel blocker for improving walking in patients with MS; and Zanaflex capsules and tablets (tizanidine hydrochloride), a short-acting drug for managing spasticity. For more information, visit the company’s website at www.acorda.com.

Advanced Cell Technology, Inc. (ACTC)

Advanced Cell Technology, Inc. (OTC: ACTC) is a biotechnology company that develops human embryonic and adult stem cell technology. The company has ownership/licensing of approximately 37 patents and approximately 190 patent applications pending in the regenerative medicine and stem cell therapy fields. It is also running clinical trials for treating macular degeneration and has a pre-clinical development pipeline focused on products for eye diseases, autoimmune and inflammatory diseases, and wound healing. For more information, visit the company’s website at www.advancedcell.com.

Advaxis, Inc. (ADXS)

Advaxis, Inc. (OTCBB: ADXS) is a biotechnology company developing immunotherapies for cancer and infectious diseases, with more than fifteen distinct constructs in development. The company’s products in the clinical development stage include: ADXS-HPV, which is being evaluated in clinical trials for cervical, head, neck and anal cancer; ADXS-PSA for prostate cancer; and ADXS-cHER2 for overexpressing cancers, such as breast and gastric cancers in humans as well as for osteosarcoma in canines. For more information, visit the company’s website at www.advaxis.com.

Akers Biosciences, Inc. (AKBS)

Akers Biosciences, Inc. (OTC: AKBS) develops and sells disposable diagnostic testing devices to facilitate time-sensitive therapeutic decisions. The company’s products include BreathScan PRO, a single-use, disposable breath alcohol detector; Metron, a simple breath test for weight loss; Tri-Cholesterol Test to screen for elevated cholesterol as a risk factor in coronary artery disease; and Vivo, a system for measuring biological markers of oxidative stress non-invasively through a breath test. For more information, visit the company’s website at www.akerslaboratories.com.

Alcobra Ltd. (ADHD)

Alcobra Ltd. (NASDAQ: ADHD) is an emerging biopharmaceutical company that develops and markets drugs for the treatment of central nervous system disorders and cognitive dysfunctions. The company is primarily focused on developing and marketing its most advanced drug, MG01CI, a non-stimulant attention deficit hyperactivity disorder drug for adults and children, which has completed phase II clinical trial studies. For more information, visit the company’s website at www.alcobra-pharma.com.

Amarantus BioScience Holdings, Inc. (AMBS)

Amarantus BioScience Holdings, Inc. (OTC: AMBS) is a development-stage biotechnology company focusing on the discovery and development of drug candidates and diagnostic blood tests to diagnose and treat human diseases. The company is developing the Mesencephalic-Astrocyte-derived Neurotrophic Factor, a therapeutic protein for treating Parkinson’s diseases; LymPro, a blood test to diagnose Alzheimer’s disease; NuroPro to diagnose neurodegenerative diseases; and BC-SeraPro to diagnose breast cancer. For more information, visit the company’s website at www.amarantus.com.

Amarin Corporation plc (AMRN)

Amarin Corporation plc (NASDAQ: AMRN) is a biopharmaceutical company engaged in developing and bringing to market therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and the therapeutic benefits of polyunsaturated fatty acids. The company’s lead product includes Vascepa, a prescription-only omega-3 fatty acid that can be used along with diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. For more information, visit the company’s website at www.amarincorp.com.

AtheroNova Inc. (AHRO)

AtheroNova Inc. (OTC: AHRO) is a development stage company engaging in the research and development, marketing, and sale of pharmaceutical preparations and pharmaceutical intellectual property. The company develops intellectual property that uses certain pharmacological compounds for the treatment of atherosclerosis, the primary cause of various cardiovascular diseases. For more information, visit the company’s website at www.atheronova.com.

Atossa Genetics, Inc. (ATOS)

Atossa Genetics, Inc. (NASDAQ: ATOS) is a healthcare company developing and marketing cellular and molecular diagnostic risk assessment products for breast cancer. The company’s diagnostic tests include the ForeCYTE Breast Health Test, which provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65; and the ArgusCYTE Breast Health Test that offers information to help inform breast cancer treatment options and monitor potential recurrence. For more information, visit the company’s website at www.atossagenetics.com.

BioSpecifics Technologies Corp. (BSTC)

BioSpecifics Technologies Corp. (NASDAQ: BSTC) is a biopharmaceutical company that is focused on developing an injectable collagenase for various clinical indications. Under the XIAFLEX name, BioSpecifics provides injectable collagenase for the treatment of adult Dupuytren's contracture patients with a palpable cord and for Peyronie’s disease, frozen shoulder, cellulite, human lipoma and canine lipoma indications as well as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs. For more information, visit the company’s website at www.biospecifics.com.

Cancer Genetics, Inc. (CGIX)

Cancer Genetics, Inc. (NASDAQ: CGIX) is an early-stage diagnostics company developing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis, and response to the treatment of cancer. The company’s tests target many cancers, including hematological, urogenital, and HPV-associated cancers. It also provides a range of non-proprietary, oncology-focused tests and laboratory services that offer critical genomic information to healthcare professionals, as well as biopharma and biotech. For more information, visit the company’s website at www.cancergenetics.com.

Can-Fite BioPharma, Ltd. (CANFY)

Can-Fite BioPharma, Ltd. (OTC: CANFY) is a biotechnology company developing drugs for treating cancer and autoimmune inflammatory diseases. Principally, the company develops CF101, which is in Phase III study for the treatment of psoriasis and has completed Phase II study for the treatment of rheumatoid arthritis and glaucoma, Phase III study for the treatment of dry eye, and Phase I study for the treatment of uveitis. For more information, visit the company’s website at www.canfite.co.il.

Catalyst Pharmaceutical Partners, Inc. (CPRX)

Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) is a specialty pharmaceutical company developing prescription drugs targeting rare neuromuscular and neurological diseases and disorders. The company’s principal product is Firdapse, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It also develops CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other central nervous disease indications; and CPP-109 for the treatment of Tourette Syndrome. For more information, visit the company’s website at www.catalystpharma.com.

Champions Oncology, Inc. (CSBR)

Champions Oncology, Inc. (OTC: CSBR) offers technology solutions that personalize the development and use of oncology drugs. The company’s Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. Through this platform, the company provides Personalized Oncology Solutions that assist physicians in developing customized treatment options for their cancer patients through tumor-specific data obtained from drug studies and related personalized oncology services. For more information, visit the company’s website at www.championsoncology.com.

CytRx Corporation (CYTR)

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company, specializes in the enhanced delivery of proven oncology therapies to treat cancer. The company’s novel linker platform technology can be utilized with multiple chemotherapeutic agents and could allow for greater concentration of drug at tumor sites while minimizing side effects. With no debt and significant cash resources, CytRx has the capital position necessary to support near and mid-term milestones across its entire oncology pipeline. For more information, visit the company’s website at www.cytrx.com.

DS Healthcare Group, Inc. (DSKX)

DS Healthcare Group, Inc. (NASDAQ: DSKX) develops and markets hair, skin, health and personal care products. The company’s products include the Revita shampoo and Revita.Cor conditioner for hair growth stimulation; Spectral.DNC spray formula, Spectral.DNC-L lotion, and Spectral DNC-N to re-grow hair as well as Spectral.RS, a topical treatment for men and women with advanced androgenic alopecia; and Dandrene, an antifungal shampoo to treat itchy scalp and dandruff. For more information, visit the company’s website at www.dslaboratories.com.

Echo Therapeutics, Inc. (ECTE)

Echo Therapeutics, Inc. (NASDAQ: ECTE) is a transdermal medical device company. The company is involved in developing Prelude SkinPrep System, a platform technology that would allow painless skin permeation and enable needle-free drug delivery and analyte extraction; and Symphony tCGM System, a non-invasive, wireless, and transdermal continuous glucose monitoring system for use in hospital critical care units and for patients with diabetes. For more information, visit the company’s website at www.echotx.com.

Enzo Biochem, Inc. (ENZ)

Enzo Biochem, Inc. (NYSE: ENZ) is an integrated life sciences and biotechnology company that focuses on diagnostic and research products. The company operates in three segments: the Clinical Labs segment offers clinical laboratory tests/procedures used in general patient care; the Life Sciences segment develops products and tools for life sciences, drug development, and clinical research customers; and the Therapeutics segment researches and develops therapeutic drug candidates for gastrointestinal, infectious and other diseases. For more information, visit the company’s website at www.enzo.com.

Evoke Pharma, Inc. (EVOK)

Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused on gastrointestinal disease treatments. The company was established by experienced specialty pharmaceutical executives with a successful track record of acquiring, developing, registering, and marketing pharmaceutical products in the United States. For more information, visit the company’s website at www.evokepharma.com.

Galena Biopharma, Inc. (GALE)

Galena Biopharma, Inc. (NASDAQ: GALE) is a biopharmaceutical company that focuses on developing oncology treatments to address major unmet medical needs to advance cancer care. The company’s lead product candidate includes NeuVax, which is in clinical trials for preventing the recurrence of breast cancer. The company is also developing the Folate Binding Protein-E39, a targeted vaccine that is in clinical trials for the prevention of recurrence in gynecological cancers. For more information, visit the company’s website at www.galenabiopharma.com.

GW Pharmaceuticals plc (GWPH)

GW Pharmaceuticals plc (NASDAQ; GWPH) engages in the research, development, and marketing of cannabinoid prescription medicines. The company primarily offers Sativex, an oromucosal spray, for the treatment of multiple sclerosis symptoms, cancer pain, and neuropathic pain, but is also focusing on the clinical development of Sativex for use in cancer pain treatment. The company also has two product candidates in clinical trials in the fields of diabetes and inflammation. For more information, visit the company’s website at www.galenabiopharma.com.

Heat Biologics, Inc. (HTBX)

Heat Biologics, Inc. (NASDAQ: HTBX) is biopharmaceutical company developing cellular therapeutic vaccines for cancers and infectious diseases. The company is developing the Immune Pan Antigen Cytotoxic therapy, a platform technology that delivers human cells that are reprogrammed to pump out various cancer associated antigens together with a potent immune adjuvant. The company’s products include the HS-HIV product candidate for the treatment and prevention of HIV. For more information, visit the company’s website at www.heatbio.com.

Inovio Pharmaceuticals, Inc. (INO)

Inovio Pharmaceuticals, Inc. (NYSE: INO) and its subsidiaries engage in discovering and developing synthetic vaccines and immune therapies for cancers and other infectious diseases. Inovio’s DNA-based SynCon technology facilitates the design of vaccines capable of providing cross-protection against new, unmatched strains of pathogens, such as influenza, while its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. For more information, visit the company’s website at www.inovio.com.

Invivo Therapeutics Holdings Corp. (NVIV)

Invivo Therapeutics Holdings Corp. (OTCBB: NVIV) is a development stage company engaged in the development and commercialization of biopolymer scaffolding devices for the treatment of spinal cord injuries, peripheral nerve injuries, and other neurotrauma conditions. The company also aims to develop and commercialize biocompatible hydrogel for use as dural sealants and replacements and nerve conduits and for local controlled release of methylprednisolone to treat spinal cord injuries and peripheral nerve injuries. For more information, visit the company’s website at www.invivotherapeutics.com.

Kips Bay Medical, Inc. (KIPS)

Kips Bay Medical, Inc. (NASDAQ: KIPS) is a medical device company that manufactures its external saphenous vein support technology (eSVS Mesh) for use in coronary artery bypass grafting (CABG) surgery. Its eSVS Mesh is a flexible, semi-compliant, kink-resistant, tubular-shaped device knitted from nickel/titanium wire and is designed to be fitted like a sleeve on the outside of saphenous vein grafts to strengthen these grafts used in CABG surgery. For more information, visit the company’s website at www.kipsbaymedical.com.

Mast Therapeutics, Inc. (MSTX)

Mast Therapeutics, Inc. (NYSE: MSTX) is a biopharmaceutical company developing therapies for life-threatening diseases. The company’s lead product candidate is MST-188, which has hemorheologic, cytoprotective, and anti-inflammatory properties and is in phase 3 study for the treatment of sickle cell disease in patients. For more information, visit the company’s website at www.masttherapeutics.com.

Metastat, Inc. (MTST)

Metastat, Inc. (OTC: MTST) is a life sciences company that provides proprietary platform technologies for the treatment of systemic metastasis. Its MetaSite Breast and MenaCalc diagnostic product lines are designed to predict the probability of cancer metastasizing and intended to allow clinicians to customize cancer treatment decisions by identifying and differentiating high-risk patients who need aggressive therapy and sparing low-risk patients from the harmful side effects and expense of chemotherapy and radiation therapies. For more information, visit the company’s website at www.metastat.com.

NeoStem, Inc. (NBS)

NeoStem, Inc. (NASDAQ: NBS) develops proprietary cell therapy products. It is involved in: manufacturing cell therapy-based products; product and process development; cell and tissue processing; regulatory support, storage, distribution and delivery; and consulting services. The company also provides contract development and manufacturing services to clients advancing product candidates for regenerative medicine; adult stem cell collection and storage services; and therapy development utilizing T-cells for autoimmune and inflammatory conditions. For more information, visit the company’s website at www.neostem.com.

Northwest Biotherapeutics, Inc. (NWBO)

Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) is a development-stage biotechnology company engaging in the discovery, development and commercialization of immunotherapy products for treating cancers. The company’s DCVax uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer. The company also develops DCVax-L, which is under Phase III clinical trials for glioblastoma multiforme brain cancer and ovarian cancer. For more information, visit the company’s website at www.nwbio.com.

OHR Pharmaceutical, Inc. (OHRP)

OHR Pharmaceutical, Inc. (NASDAQ: OHRP) is a biotechnology company. The company’s products include Squalamine, an anti-angiogenic small molecule with a novel intracellular mechanism that inhibits vascular endothelial, platelet derived and basic fibroblast growth factors to treat the wet form of age-related macular degeneration. It also offers OHR/AVR 118, which is in clinical trial for the treatment of cancer cachexia, a multi-symptom wasting disorder. For more information, visit the company’s website at www.ohrpharmaceutical.net.

OncoSec Medical Incorporated (ONCS)

OncoSec Medical Incorporated (ONCS) OncoSec Medical Incorporated (OTC: ONCS) designs and develops novel cancer therapeutic products. The company’s products combine proprietary delivery technology with a novel DNA-based immunotherapeutics, known as OMS ElectroOncology. Its clinical programs include The NeoPulse approach, which is in clinical trials for the treatment of recurrent head, neck and breast cancer; and three clinical trials assessing the cancer-destroying and tissue-sparing properties of the ImmunoPulse technology. For more information, visit the company’s website at www.oncosec.com.

Opexa Therapeutics, Inc. (OPXA)

Opexa Therapeutics, Inc. (NASDAQ: OPXA) is a biopharmaceutical company that develops personalized cellular therapies to treat multiple sclerosis (MS) using its proprietary T-cell technology. Its leading therapy candidate includes Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. For more information, visit the company’s website at www.opexatherapeutics.com.

Organovo Holdings, Inc. (ONVO)

Organovo Holdings, Inc. (NYSE: ONVO) develops three-dimensional (3D) bioprinting technology for creating functional human tissues for research and medical applications. The company’s 3D NovoGen bioprinting technology works across various tissue and cell types, and allows for the placement of cells in desired pattern. For more information, visit the company’s website at www.organovo.com.

Oxygen Biotherapeutics, Inc. (OXBT)

Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) is a development stage company developing biotechnology products that deliver oxygen to target tissues in the body. The company develops Oxycyte, an oxygen carrier for use in situations of acute ischemia, which is in clinical trial for the treatment of traumatic brain injury. The company also offers the Dermacyte line of topical cosmetic products, which promote the appearance of skin health, and Wundecyte, a wound-healing gel. For more information, visit the company’s website at www.oxybiomed.com.

PharmAthene, Inc. (PIP)

PharmAthene, Inc. (NYSE: PIP) is a biodefense company developing medical countermeasures against biological and chemical threats. The company’s product candidates include: SparVax, an anthrax vaccine which has completed a Phase II clinical trial for post-exposure prophylaxis; Valortim, a human monoclonal antibody which has completed a Phase I clinical trial for the prevention and treatment of anthrax infection; and rBChE bioscavanger, a medical countermeasure for nerve agent poisoning. For more information, visit the company’s website at www.pharmathene.com.

PhotoMedex, Inc. (PHMD)

PhotoMedex, Inc. (NASDAQ: PHMD) is a skin health company that provides integrated disease management and aesthetic solutions to dermatologists, professional aestheticians, and consumers. The company offers products and services that address skin diseases and conditions, including psoriasis and acne, and provides skin health solutions to spa markets, retailers, and online and infomercial outlets. The company also provides a range of home-use devices under the no!no! brand for hair removal, acne treatment, and skin rejuvenation. For more information, visit the company’s website at www.photomedex.com.

Prima BioMed Ltd. (PBMD)

Prima BioMed Ltd. (NASDAQ: PBMD) is a biotechnology company researching and developing licensed medical biotechnology products in Australia. The company’s lead product is CVac, a cancer vaccine for patients in remission, which has completed two human clinical trials. The company is also developing oral vaccine against human papilloma virus, a virus associated with development of cervical cancer. For more information, visit the company’s website at www.primabiomed.com.au.

Regado Biosciences, Inc. (RGDO)

Regado Biosciences, Inc. (NASDAQ: RGDO) is a biopharmaceutical company discovering and developing antithrombotic drug systems for acute and sub-acute cardiovascular and other indications. The company’s lead product includes REG1, an anticoagulant in clinical trials for use in patients with cardiovascular conditions who are undergoing coronary intervention. The company’s products under development also include REG2 for venous thrombosis indications treatment; and REG3, an antiplatelet therapy for diabetic vasculopathy and other inflammatory diseases. For more information, visit the company’s website at www.regadobio.com.

Rosetta Genomics Ltd. (ROSG)

Rosetta Genomics Ltd. (NASDAQ: ROSG) develops diagnostic tools for microRNAs, a group of genes produced using instructions encoded in DNA. The company offers diagnostic tests, including miRview mets2, a microRNA-based diagnostic used to identify 42 tumor types including carcinomas, soft tissue tumors, lymphoma, and other malignancies; and miRview meso used to differentiate mesothelioma, a cancer connected to asbestos exposure and other risk factors, from other carcinomas in the lung and pleura. For more information, visit the company’s website at www.rosettagenomics.com.

SciClone Pharmaceuticals, Inc. (SCLN)

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) provides therapies for the treatment of oncology, infectious diseases, cardiovascular, urological, respiratory, and central nervous system disorders in China and internationally. Its principal product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as a vaccine adjuvant and chemotherapy adjuvant for cancer patients with weakened immune systems. For more information, visit the company’s website at www.sciclone.com.

Spectrum Pharmaceuticals, Inc. (SPPI)

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) is a biotechnology company engaged in acquiring, developing, and marketing prescription drug products for hematology and oncology. The company’s oncology products include FUSILEV for patients with osteosarcoma after high-dose methotrexate therapy; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; and ZEVALIN, a prescribed form of cancer therapy which combines a source of radiation with an antibody. For more information, visit the company’s website at www.sppirx.com.

Stemline Therapeutics, Inc. (STML)

Stemline Therapeutics, Inc. (NASDAQ: STML) is a clinical-stage biopharmaceutical company focusing on the discovery, acquisition, development and commercialization of proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. In addition to developing StemScreen platform technology for the identification of novel CSC-directed compounds, Stemline is also developing SL-401, a biologic-drug conjugate which has completed Phase I/II clinical trial for relapsed/refractory acute myeloid leukemia. For more information, visit the company’s website at www.stemline.com.

Synergy Pharmaceuticals Inc. (SGYP)

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) is a biopharmaceutical company that focuses on developing drugs for treating gastrointestinal (GI) disorders and diseases. Synergy’s lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist which has completed Phase IIa clinical trials for the treatment of chronic idiopathic constipation GI disorders and is in Phase IIb clinical trials for the treatment of constipation-predominant irritable bowel syndrome GI disorders. For more information, visit the company’s website at www.synergypharma.com.

Targeted Medical Pharma, Inc. (TRGM)

Targeted Medical Pharma, Inc. (OTC: TRGM) is a biotechnology company that develops and distributes prescription medical foods for chronic disease treatment, convenience kits, and generic pharmaceuticals to physicians and pharmacies in the United States and Middle East. The company also provides technical analysis of certain diagnostic procedures, in clinical and laboratory settings, to clinicians, the pharmaceutical industry, and governmental entities in research trials. For more information, visit the company’s website at www.targetedmedicalpharma.com.

Trovagene Inc. (TROV)

Trovagene Inc. (NASDAQ: TROV) develops diagnostic technologies for use in patient/disease screening and monitoring in various medical disciplines. The company’s urine-based testing platform helps to enhance cancer care management and women’s healthcare. The company’s technology is also applied in various testing, including tumor detection and monitoring, prenatal genetic testing, infectious diseases, tissue transplantation, and forensic identification, as well as for patient selection in clinical trials. For more information, visit the company’s website at www.trovagene.com.

Venaxis, Inc. (APPY)

Venaxis, Inc. (NASDAQ: APPY) develops and commercializes products for unmet diagnostic and therapeutic needs. Its lead product candidate includes APPY1, a blood-based diagnostic test designed to aid in the evaluation of patients for acute appendicitis. The company, through its license agreement with Washington University in St. Louis, develops, markets, distributes, imports, and exports luteinizing hormone and/or follicle-stimulating hormone products for cattle, equine, and swine animals. For more information, visit the company’s website at www.venaxis.com.

 
Twitter

For more frequent updates, follow us on Twitter!

Home     About Us     IR Services     Investors     Partners     Market Research     Blog     Contact     Disclaimer

© 2012 Mission Investor Relations. All rights reserved.
3645 Marketplace Blvd.   Suite 130-280   Atlanta, GA 30344   404-941-8975